Niclosamide is a promising antifibrotic agent, which significantly reduced liver enzymes and reduced inflammation by decreasing TNF-α, IL-6, NF-kB and p-STAT3 in PBC animal model (115). Here, NFKB1 is linked to primary biliary cholangitis.